Is Serum Irisin Level a Biomarker in Diabetic Polyneuropathy?
Starting soon
Conditions studied: Polyneuropathies, Diabetic Complications Neurological, Diabetes Mellitus Type 2
In brief
Diabetic polyneuropathy is a common complication of type 2 diabetes mellitus associated with sensory impairment and functional disability. Irisin is a myokine that has been implicated in glucose metabolism and neuroprotection. This prospective observational case-control study aims to evaluate serum irisin concentrations in patients with diabetic polyneuropathy compared with diabetic patients without neuropathy and healthy controls, and to investigate whether serum irisin may serve as a biomarker for diabetic polyneuropathy.
Key facts
- Study ID
- NCT07734597
- Run by
- GÜLDEN ANATACA
- People needed
- 81
- Starts
- 2026-07-30
- Expected to finish
- 2026-09-30
- Last updated by the study team
- 2026-07-29
Who can join
Age: 30 and older, up to 75. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Age between 30 and 75 years
- Diagnosis of Type 2 Diabetes Mellitus for at least 1 year (for diabetic groups)
- Ability to understand and sign informed consent
- Willingness to participate in the study
You may not qualify if…
- Neuropathy due to causes other than diabetes (e.g., vitamin B12 deficiency, chronic alcohol use, chemotherapy-induced neuropathy)
- Chronic kidney disease (eGFR <60 mL/min/1.73 m²)
- Active infection
- Myopathies or other muscle diseases
- Central nervous system diseases (e.g., stroke, Parkinson disease)
- Severe orthopedic conditions impairing mobility
- Inability or unwillingness to provide informed consent
Where it is running
- Kanuni Sultan Süleyman Training and Research Hospital — Istanbul, Turkey (Türkiye)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.